Prothrombin consumption as an indicator of hemorrhagic phenotype in mild platelet function disorders
Corresponding Author
Antoine Babuty
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Correspondence
Antoine Babuty, Laboratoire d'Hématologie Biologique, CHU Hôtel-Dieu, Nantes, Cedex 1, France.
Email: [email protected]
Search for more papers by this authorCamille Debord
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorNicolas Drillaud
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorMarion Eveillard
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorMarc Trossaert
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorCatherine Ternisien
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorMarianne Sigaud
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorEmmanuelle Cador
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorMarie C. Béné
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorMarc Fouassier
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorCorresponding Author
Antoine Babuty
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Correspondence
Antoine Babuty, Laboratoire d'Hématologie Biologique, CHU Hôtel-Dieu, Nantes, Cedex 1, France.
Email: [email protected]
Search for more papers by this authorCamille Debord
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorNicolas Drillaud
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorMarion Eveillard
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorMarc Trossaert
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorCatherine Ternisien
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorMarianne Sigaud
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorEmmanuelle Cador
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorMarie C. Béné
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Search for more papers by this authorMarc Fouassier
Nantes Université, CHU Nantes, Service d'Hématologie Biologique, Nantes, France
Nantes Université, CHU Nantes, Centre de Ressource et de Compétence—Maladies Hémorragiques Constitutionnelles, Nantes, France
Search for more papers by this authorAbstract
Background
The bleeding risk of patients with mild platelet function disorders is difficult to assess and their phenotype remains ill-explored.
Aim
This study was designed to establish a comprehensive biological phenotype of patients with mild platelet function disorders.
Methods
Twenty patients were included with persistent abnormal light transmission aggregometry (LTA). The ISTH bleeding assessment tool (ISTH-BAT) was assessed to identify laboratory analyses associated with an abnormal hemorrhagic score.
Results
The majority of patients had defects that might affect Gαi protein signaling pathways or minor abnormalities. No LTA nor flow cytometry parameters were associated with an above-normal hemorrhagic score. However, prothrombin consumption, which corresponds to the ratio of serum residual factor II to plasma residual factor II, was significantly higher (p = .006) in the abnormal ISTH-BAT group (mean = 14%, SD = 6) compared with the normal ISTH-BAT group (mean = 8%, SD 4). Prothrombin consumption was significantly associated with ISTH-BAT score (r = .5287, IC 95% 0.0986–0.7924, p = .0165).
Conclusion
In this group of patients, there was an association between a pathological bleeding score and increased prothrombin consumption. This test could be used as an additional indicator of platelet function abnormality liable to be related to bleeding risk.
CONFLICT OF INTEREST STATEMENT
The authors have no competing interests to declare that are relevant to the content of this article.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| ejh14079-sup-0001-Supplemental_Table_1.docWord document, 68 KB | Table S1. Results of first line laboratory analysis of the 20 patients included in the study. |
| ejh14079-sup-0002-Supplemental_Table_2.docWord document, 153 KB | Table S2. Results of the specialized laboratory analysis of the 20 patients included in the study. |
| ejh14079-sup-0003-Supplemental_Table_3.docWord document, 69.5 KB | Table S3. Comparison of specialized biological analyses between normal and abnormal ISTH-BAT groups. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Podda G, Femia EA, Pugliano M, Cattaneo M. Congenital defects of platelet function. Platelets. 2012; 23(7): 552-563.
- 2Gresele P, Harrison P, Bury L, et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost. 2014; 12(9): 1562-1569.
- 3Nurden AT, Nurden P. Inherited disorders of platelet function: selected updates. J Thromb Haemost. 2015; 13(Suppl 1): S2-S9.
- 4Gresele P, Bury L, Falcinelli E. Inherited platelet function disorders: algorithms for phenotypic and genetic investigation. Semin Thromb Hemost. 2016; 42(3): 292-305.
- 5Nava T, Rivard G-E, Bonnefoy A. Challenges on the diagnostic approach of inherited platelet function disorders: is a paradigm change necessary? Platelets. 2018; 29(2): 148-155.
- 6Hayward CPM. How I investigate for bleeding disorders. Int J Lab Hematol. 2018; 40(Suppl 1): 6-14.
- 7Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010; 8(9): 2063-2065.
- 8Lowe GC, Lordkipanidzé M, Watson SP. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost. 2013; 11(9): 1663-1668.
- 9Gresele P, Orsini S, Noris P, et al. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: a communication from the platelet physiology SSC. J Thromb Haemost. 2020; 18(3): 732-739.
- 10Hayward CPM, Moffat KA, Raby A, et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol. 2010; 134(6): 955-963.
- 11Harrison P, Mackie I, Mumford A, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011; 155(1): 30-44.
- 12Hayward CPM, Moffat KA, Plumhoff E, van Cott EM. Approaches to investigating common bleeding disorders: an evaluation of North American coagulation laboratory practices. Am J Hematol. 2012; 87(Suppl 1): S45-S50.
- 13Gresele P. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015; 13(2): 314-322.
- 14Gresele P, Bury L, Mezzasoma AM, Falcinelli E. Platelet function assays in diagnosis: an update. Expert Rev Hematol. 2019; 12(1): 29-46.
- 15Ibrahim-Kosta M, Alessi MC, Hezard N. Laboratory techniques used to diagnose constitutional platelet dysfunction. Hamostaseologie. 2020; 40(4): 444-459.
- 16Gomez K, Anderson J, Baker P, et al. Clinical and laboratory diagnosis of heritable platelet disorders in adults and children. British Journal of Haematology. 2021; 195(1): 46-72.
- 17Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost. 2013; 11(6): 1183-1189.
- 18Rubak P, Nissen PH, Kristensen SD, Hvas A-M. Investigation of platelet function and platelet disorders using flow cytometry. Platelets. 2016; 27(1): 66-74.
- 19van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function diagnostics. Semin Thromb Hemost. 2018; 44(3): 197-205.
- 20van Asten I, Schutgens REG, Baaij M, et al. Validation of flow cytometric analysis of platelet function in patients with a suspected platelet function defect. J Thromb Haemost. 2018; 16(4): 689-698.
- 21Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H. Diagnosis of platelet function disorders: a standardized, rational, and modular flow cytometric approach. Platelets. 2018; 29(4): 347-356.
- 22Fouassier M, Babuty A, Debord C, Béné MC. Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints. Cytometry B Clin Cytom. 2020; 98(6): 464-475.
- 23van Asten I, Blaauwgeers M, Granneman L, et al. Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency. J Thromb Haemost. 2020; 18(3): 706-713.
- 24Halliez M, Fouassier M, Robillard N, et al. Detection of phosphatidyl serine on activated platelets’ surface by flow cytometry in whole blood: a simpler test for the diagnosis of Scott syndrome. British Journal of Haematology. 2015; 171(2): 290-292.
- 25Cai H, Mullier F, Frotscher B, et al. Usefulness of flow cytometric mepacrine uptake/release combined with CD63 assay in diagnosis of patients with suspected platelet dense granule disorder. Semin Thromb Hemost. 2016; 42(3): 282-291.
- 26Kluge H, Bolle M, Reuter R, Werner S, Zahlten W, Prudlo J. Serotonin in platelets: comparative analyses using new enzyme immunoassay and HPLC test kits and the traditional fluorimetric procedure. J Lab Med. 1999; 23(6): 360-364.
- 27Fouassier M, Bourgerette E, Libert F, Pouplard C, Marques-Verdier A. Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin-induced thrombocytopenia: comparison with reference method by [C]-serotonin release assay. J Thromb Haemost. 2006; 4(5): 1136-1139.
- 28Dawood BB, Lowe GC, Lordkipanidzé M, et al. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood. 2012; 120(25): 5041-5049.
- 29Dawood BB, Wilde J, Watson SP. Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A(2) pathways. Platelets. 2007; 18(5): 329-345.
- 30Adler M, Kaufmann J, Alberio L, Nagler M. Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. J Thromb Haemost. 2019; 17(7): 1104-1112.
- 31Rashid A, Moiz B, Karim F, Shaikh MS, Mansoori H, Raheem A. Use of ISTH bleeding assessment tool to predict inherited platelet dysfunction in resource constrained settings. Scand J Clin Lab Invest. 2016; 76(5): 373-378.
- 32Busuttil-Crellin X, McCafferty C, Van Den Helm S, et al. Guidelines for panel design, optimization, and performance of whole blood multi-color flow cytometry of platelet surface markers. Platelets. 2020; 31(7): 845-852.
- 33Kaur H, Borhany M, Azzam H, Costa-Lima C, Ozelo M, Othman M. The utility of international society on thrombosis and Haemostasis-bleeding assessment tool and other bleeding questionnaires in assessing the bleeding phenotype in two platelet function defects. Blood Coagul Fibrinolysis. 2016; 27(5): 589-593.
- 34Owen CAJ, Thompson JHJ. Soybean phosphatides in prothrombin-consumption and thromboplastin-generation tests: their use in recognizing “thrombasthenic hemophilia”. Am J Clin Pathol. 1960; 33: 197-208.
- 35Quick AJ. The prothrombin consumption time as a determinant of platelet function. Am J Clin Pathol. 1974; 61(4): 449-457.
- 36Weiss HJ, Vicic WJ, Lages BA, Rogers J. Isolated deficiency of platelet procoagulant activity. Am J Med. 1979; 67(2): 206-213.
- 37Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity—a comparison with Scott syndrome. Blood. 1997; 89(5): 1599-1611.
- 38Satta N, Toti F, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome: an inherited defect of the procoagulant activity of platelets. Platelets. 1997; 8(2–3): 117-124.
- 39Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost. 2009; 35(2): 233-241.
- 40Flores-Nascimento MC, Orsi FLA, Yokoyama AP, et al. Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagul Fibrinolysis. 2012; 23(1): 75-77.
- 41Nurden P, Stritt S, Favier R, Nurden AT. Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy. Haematologica. 2021; 106(2): 337-350.
